[Correspondence] 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia

Motoi Suzuki and colleagues1 found that 23-valent pneumococcal polysaccharide vaccine (PPV23) showed low to moderate effectiveness against vaccine serotype pneumococcal pneumonia in Japanese people aged 65 years or older treated at four community-based hospitals from September, 2011, to August, 2014. As the authors wrote, 7-valent pneumococcal conjugate vaccine (PCV7) became commercially available for Japanese children in February, 2010, and it was incorporated into the routine immunisation schedule for children in April, 2013.

Source: The Lancet Infectious Diseases - June 22, 2017 Category: Infectious Diseases Authors: Tetsuya Tanimoto, Eiji Kusumi, Kazutaka Hosoda, Tamae Hamaki, Kenzo Takahashi Tags: Correspondence Source Type: research